| Literature DB >> 30670088 |
Johannes Gleich1, Daniel Pfeufer1, Christian Zeckey1, Wolfgang Böcker1, Markus Gosch2, Christian Kammerlander1, Carl Neuerburg3.
Abstract
BACKGROUND: Multimorbidity and polypharmacy are common challenges in the treatment of older trauma patients. Therefore, various integrated care models were developed over the last few years, merging the expertise of geriatricians and trauma surgeons. The aim of this study was to evaluate, if the number of prescriptions of potentially inappropriate medication (PIM) could be reduced in these patients by an interdisciplinary co-managed concept compared to conventional trauma care.Entities:
Keywords: Frailty; Hip fracture; Humeral fracture; Integrated care; Pharmacotherapy
Mesh:
Year: 2019 PMID: 30670088 PMCID: PMC6341562 DOI: 10.1186/s40001-019-0362-0
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Most relevant PIMs in orthogeriatric setting
| Drug | Reason |
|---|---|
| NSAID | Increased risk for: gastrointestinal ulcer, myocardial infarction (MI), stroke, hypertensive crisis, impaired renal function |
| Benzodiazepines | Increased risk for sedation, delirium, falls |
| Tricyclic antidepressants at preexisting dementia | Increased risk for delirium, falls, urinary retention, cardiac arrythmia |
| Opiates (long acting) at preexisting dementia | Cognitive worsening |
| Antimuscarinic drugs at preexisting dementia | Cognitive worsening |
| Neuroleptics (long acting) at preexisting Parkinson´s disease | Cognitive worsening |
| SSRI-type antidepressants at hyponatremia | Cognitive worsening, increased risk of falls, negative effect on bone metabolism |
| Antibiotics | Increased risk for: |
| Antihistamines (especially H1) | Increased risk for: constipation, dizziness, cognitive impairment |
| Statins (except at preexisting MI, coronary heart disease, stroke) | Muscle weakness, increased risk for rhabdomyolysis |
| Urologicals/incontinence medication (except indispensable) | Increased risk for: cognitive worsening, falls |
| Glucocorticoids (except indispensable) | Confusion, negative effect on bone metabolism |
| Digitalis (except indispensable) | Cardiac arrythmia |
| Diuretics (except indispensable, e.g., at renal insufficiency) | Increased risk for: dizziness, dehydration, confusion, electrolyte imbalance |
| Specific antihypertensive drugs (clonidine, reserpine, propranolol, hydralazine) | Increased risk for: cognitive impairment, depression, orthostatic hypotension, sedation |
Baseline characteristics
| CTC ( | OGC ( | ||
|---|---|---|---|
| Age (years), mean (SD) | 81.54 (± 6.91) | 83.39 (± 6.959) | 0.201 |
| Gender (female) | 87.8% ( | 68.5% ( | 0.027 |
| ASA score | 0.406 | ||
| 1–2 | 29.3% ( | 22.2% ( | |
| 3 | 68.3% ( | 74.1% ( | |
| 4–5 | 2.4% ( | 3.7% ( | |
| Charlson comorbidity index, mean (SD) | 2.51 (± 1.989) | 2.09 (± 1.733) | 0.281 |
| Length of stay (days), mean (SD) | 12.98 (± 4.43) | 13.36 (± 5.516) | 0.536 |
| Proximal humerus | 11.00 (3.661) | 10.00 (6.453) | 0.656 |
| Femoral | 13.70 (4.519) | 14.67 (4.817) | 0.392 |
| Type of fracture | 0.440 | ||
| Proximal humerus | 26.8% ( | 22.2% ( | |
| Femoral | |||
| Trochanteric | 29.3% ( | 29.6% ( | |
| Femoral neck | 41.5% ( | 37.0% ( | |
| Periprosthetic | 2.4% ( | 11.1% ( | |
| Type of treatment | 0.218 | ||
| Femoral | |||
| Osteosynthesis | 50.0% ( | 50.0% ( | |
| Prosthesis | 50.0% ( | 50.0% ( | |
| Humeral | |||
| Osteosynthesis | 54.5% ( | 91.7% ( | |
| Prosthesis | 45.5% ( | 8.3% ( | |
| Time to surgery | |||
| Femoral | 0.134 | ||
| < 24 h | 93.3% ( | 81.0% ( | |
| 24 h | 6.7% ( | 19.0% ( | |
| Humeral | 0.901 | ||
| < 24 h | 27.3% ( | 25.0% ( | |
| > 24 h | 72.7% ( | 75.0% ( | |
| GFR (ml/min) | 66.93 (± 19.865) | 69.93 (± 21.474) | 0.496 |
| Creatinine (mg/dl) | 0.945 (± 0.357) | 1.11 (± 0.453) | 0.056 |
| Vit. D | 0.213 | ||
| < 20 ng/ml | 69.2%( | 84.4% ( | |
| > 20 ng/ml | 30.8%( | 15.6%( | |
| Not stated | |||
| Discharged to | |||
| Femoral | 0.777 | ||
| Own home | 13.3% ( | 14.3% ( | |
| Nursing home | 10.0% ( | 4.8% ( | |
| Rehabilitation unit | 63.3% ( | 71.4% ( | |
| Short-term nursing | 13.3% ( | 9.5% ( | |
| Humeral | 0.169 | ||
| Own home | 72.7% ( | 58.3% ( | |
| Nursing home | 0% ( | 16.7% ( | |
| Rehabilitation unit | 9.1% ( | 25.0% ( | |
| Short-term nursing | 18.2% ( | 0% ( | |
Fig. 1Use of PIMs: Illustration of the use of PIMs in either OGC- or CTC-treated patients
Fig. 2Distribution of PIMs: see Table 1 for detailed description of each group of drugs/their adverse effects